ClinicalTrials.gg
RecruitingNCT05480826GENIUpdated Apr 23, 2024

Familial and Functional Study of Genetic Variants Identified in People With Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder or Resistant Depression

An interventional study of study of the transmission of genetic variants in Psychiatric Disorder, sponsored by Fondation FondaMental. Recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-23.

Sponsored by Fondation FondaMental · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Genetic analyses conducted on patient with psychiatric disorders assessed at the expert centres resulted in the identific action of genetic variants associated with psychiatric disorders (Courtois, 2020). These data require further genetic and functional analyses. The first objective of this study is to investigate the disease-related inheritance of genetic variants in the families of individuals in whom these variants have been identified. The second objective is to explore the functional consequences of disease-associated genetic variants in patients cells and those of their relatives with and without these variants.

The present project aims to enrich existing biocollections with DNA from blood or saliva from relatives of patients identified with genetic variants. In addition, we wish to collect hair follicules from patients with identified genetic variants of interest and their family members who wish to participate in the study. These hair samples with SNA will be used to dedifferentiate the isolated cells into induced pluripotent stem cells (IPSCs), and then to differentiate them into cells expressing the gene of interest, such as neurons or astrocytes, or into more complex systems, such as brain organoids.

02

Conditions studied

  • Psychiatric Disorder

Browse trials for

03

In context

Mental Disorders

1,746 studies on the registry are indexed under Mental Disorders; 350 are open to participants now.

This study's planned enrollment of 50 is below the median of 100 across 1,305 interventional studies indexed under Mental Disorders.

Browse Mental Disorders studies →

Lead sponsor

Fondation FondaMental is the lead sponsor of 5 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For patients:
  • Subjects suffering from (according to DSM IV criteria) : Bipolar disorder, Unipolar depression, Schizophrenia, Autism spectrum disorder
  • Age over 18 years
  • Subject affiliated to the social security system
  • Including patients under guardianship, curatorship,
  • Patients included in the Fondation FondaMental cohort whose genetic analyses have revealed the need for comparative and functional genetic studies.
  • Having signed the consent form

For relatives :

  • Age over 18 years
  • Relative of patient included in the Fondattion FondaMental cohort
  • Including relative under guardianship, curatorship
  • Having signed the consent
  • Affiliated to social security

Exclusion criteria

Exclusion Criteria:

  • For all subjects:
  • Any condition that, in the opinion of the investigator, would make the subject's participation in the study undesirable or that would compromise compliance with the protocol
  • Persons deprived of liberty
  • Inability to understand French
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Other
    Patients

    Subject suffering from (according to DSM IV criteria) * bipolar disorder * unipolar depression * schizophrenia * autism spectrum disorder Collection of hair follicle cells

    Genetic: study of the transmission of genetic variants

  • Other
    Relatives

    Relatives of enrolled patients suffering from psychiatric disorder. * test to detect psychiatric disorders * blood or saliva sampling for genomic DNA extraction * Collection of hair follicle cells

    Genetic: study of the transmission of genetic variants

Interventions

  • Geneticstudy of the transmission of genetic variants

    the genetic variants of interest will be investigated by sequencing or genotyping on genomic DNA

06

What researchers measure

Primary outcomes

  1. Measure of the probability of having a psychiatric disorder given the presence of the genetic variant studied.

    Test for psychiatric disorders Study of the genetic variant of interest by sequencing or genotyping on genomic DNA.

    Time frame: through study completion, an average of 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Sep 2027, 54 months after the start.

Of 668 non-industry interventional studies with no phase under Mental Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 45. This study's planned 54 months is above that.

Counting every sponsor, half of 682 studies reached it within 29 months; a quarter within 13 and three quarters within 45.

Mental Disorders covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2022
First posted
Jul 29, 2022
StartActual
Mar 15, 2023
Primary completionEst.
Sep 15, 2027
CompletionEst.
Sep 15, 2028
Last update
Apr 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05480826
Lead sponsor
Fondation FondaMental
Responsible party
Sponsor
First posted
Jul 29, 2022
Start date
Mar 15, 2023
Primary completion
Sep 15, 2027 (estimated)
Completion
Sep 15, 2028 (estimated)
Last update
Apr 23, 2024

Study contacts

Stephane JAMAIN, PhD
Contact
stephane.jamain@inserm.fr
149813775 ext. +33
Marion Leboyer, MD PhD
study chair · Fondation FondaMental
Stephane JAMAIN, PhD
study director · Institut National de la Santé Et de la Recherche Médicale, France

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion